State Street Corp Has $20.78 Billion Position in AbbVie Inc. $ABBV

State Street Corp increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,596,748 shares of the company’s stock after buying an additional 1,379,232 shares during the period. State Street Corp owned about 4.67% of AbbVie worth $20,784,646,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Premier Financial Group acquired a new stake in AbbVie during the 2nd quarter valued at approximately $250,000. Security National Bank of Sioux City Iowa IA lifted its position in shares of AbbVie by 13.3% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 16,964 shares of the company’s stock worth $4,269,000 after purchasing an additional 1,995 shares during the period. Reynders McVeigh Capital Management LLC boosted its stake in shares of AbbVie by 0.4% in the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 29,167 shares of the company’s stock valued at $7,340,000 after purchasing an additional 115 shares during the last quarter. Bullseye Investment Management LLC acquired a new stake in shares of AbbVie during the second quarter worth $170,000. Finally, Marathon Wealth Advisors LLC raised its stake in AbbVie by 0.9% during the second quarter. Marathon Wealth Advisors LLC now owns 12,292 shares of the company’s stock worth $3,093,000 after buying an additional 110 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Piper Sandler upped their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. BNP Paribas Exane upped their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of AbbVie in a report on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.64.

AbbVie Trading Up 0.4%

Shares of ABBV traded up $1.03 during trading hours on Tuesday, reaching $265.51. The stock had a trading volume of 892,624 shares, compared to its average volume of 6,538,061. The firm has a 50-day simple moving average of $255.90 and a 200 day simple moving average of $232.37. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The company has a market capitalization of $469.11 billion, a price-to-earnings ratio of 75.07, a P/E/G ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business posted $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RINVOQ gains another European indication. The European Commission approved RINVOQ (upadacitinib) for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, one or more DMARDs. The approval expands RINVOQ’s commercial reach and adds to its 11 approved EU indications, reinforcing the drug as a key growth driver for AbbVie. AbbVie Announces European Commission Approval of RINVOQ
• Positive Sentiment: AbbVie expands its AI drug-discovery strategy. AbbVie entered a multiyear collaboration with Iambic to use the company’s AI platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The partnership could improve discovery efficiency and diversify AbbVie’s long-term pipeline, although any financial benefits are likely to take years to materialize. AbbVie and Iambic Announce Collaboration
• Positive Sentiment: Allergan Aesthetics launched AA Signature: SKIN360 in the U.S. The multimodal consultation program is intended to help providers address patients’ broader aesthetic goals and could support engagement across AbbVie’s aesthetics portfolio. The near-term earnings impact is not specified. Allergan Aesthetics Debuts AA Signature
• Neutral Sentiment: Recent commentary continues to highlight AbbVie’s dividend appeal and second-quarter results, which exceeded analyst expectations for both earnings and revenue. These reports support the stock’s defensive investment case, but largely reiterate previously reported information rather than provide a new catalyst. AbbVie vs. Pfizer

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.